The Countermeasures Injury Compensation Program (CICP) provides compensation to certain individuals who suffer serious adverse events from covered diagnostic devices, medications, or therapies used to identify, prevent, or treat certain conditions.
Countermeasures eligible for compensation under the CICP include:
Countermeasures concerning pandemic influenza A and influenza A with pandemic potential (such as the 2009 H1N1 influenza A
Monovalent influenza vaccines including both the injectable and intranasal spray formulations used to prevent pandemic influenza A and influenza A with pandemic potential (such as the 2009 H1N1 influenza A)
For seasonal flu vaccine injuries, please see the VICP.
Tamiflu or Relenza when used for treatment or prevention of pandemic or potentially pandemic influenza A strains; and, peramivir (only for the treatment of the pandemic H1N1 influenza)
Any vaccine, antiviral, antimicrobial, antibiotic, other drug, or diagnostic device used to identify, prevent, or treat
***Please note that individual eligibility is determined on a case-by-case basis dependent on substantial proof that the vaccine or countermeasure caused the injury.***
The Department of Health and Human Services (HHS) has established Administrative Regulations for implementing the Countermeasures Injury Compensation Program (CICP).